This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krüüner, A.
Right arrow Articles by Hoffner, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krüüner, A.
Right arrow Articles by Hoffner, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2003, p. 2971-2973, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.2971-2973.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Discordant Resistance to Kanamycin and Amikacin in Drug-Resistant Mycobacterium tuberculosis

Annika Krüüner,1,2,3* Pontus Jureen,1 Klavdia Levina,4 Solomon Ghebremichael,1 and Sven Hoffner1

Department of Bacteriology, Swedish Institute for Infectious Disease Control,1 Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden,2 Department of Mycobacteriology, United Laboratory, Tartu University Clinics, Tartu,3 North-Estonian Regional Hospital, Tallinn, Estonia4

Received 28 January 2003/ Returned for modification 3 April 2003/ Accepted 19 June 2003

It is generally thought that there is full cross-resistance in Mycobacterium tuberculosis between the aminoglycoside drugs kanamycin and amikacin. However, kanamycin resistance and amikacin susceptibility were seen in 43 of 79 (54%) multidrug-resistant Estonian isolates, indicating that there might be a need to test the resistance of M. tuberculosis isolates to both drugs.

* Corresponding author. Mailing address: Tartu University Clinics, United Laboratory, Department of Mycobacteriology, Puusepa 1A, 50406 Tartu, Estonia. Phone: 3727 428 262. Fax: 3727 319 326. E-mail: annika.kruuner{at}kliinikum.ee.

Antimicrobial Agents and Chemotherapy, September 2003, p. 2971-2973, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.2971-2973.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Jugheli, L., Bzekalava, N., de Rijk, P., Fissette, K., Portaels, F., Rigouts, L. (2009). High Level of Cross-Resistance between Kanamycin, Amikacin, and Capreomycin among Mycobacterium tuberculosis Isolates from Georgia and a Close Relation with Mutations in the rrs Gene. Antimicrob. Agents Chemother. 53: 5064-5068 [Abstract] [Full Text]  
  • Zaunbrecher, M. A., Sikes, R. D. Jr., Metchock, B., Shinnick, T. M., Posey, J. E. (2009). Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 106: 20004-20009 [Abstract] [Full Text]  
  • Louw, G. E., Warren, R. M., Gey van Pittius, N. C., McEvoy, C. R. E., Van Helden, P. D., Victor, T. C. (2009). A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance. Antimicrob. Agents Chemother. 53: 3181-3189 [Full Text]  
  • Maus, C. E., Plikaytis, B. B., Shinnick, T. M. (2005). Molecular Analysis of Cross-Resistance to Capreomycin, Kanamycin, Amikacin, and Viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49: 3192-3197 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»